Sonnet BioTherapeutics, Inc. (NASDAQ:SONN) | WebDisclosure

Basculer en Français

10964	Companies
240021	Keywords
168770	Articles
129127	Press releases

Headlines Articles Press releases Sonnet BioTherapeutics, Inc.

Home
Companies
Sonnet BioTherapeutics, Inc.

PRESS RELEASE

published on 02/29/2024 at 22:05, 2 years 6 months ago

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability

Clinical Data Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug FHAB Technology
PRESS RELEASE

published on 02/14/2024 at 13:30, 2 years 6 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023

Financial Results Preclinical Data Public Offering Sonnet BioTherapeutics Holdings NJ NOLs
PRESS RELEASE

published on 12/21/2023 at 14:00, 2 years 8 months ago

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
PRESS RELEASE

published on 12/14/2023 at 22:15, 2 years 8 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
PRESS RELEASE

published on 10/31/2023 at 12:30, 2 years 10 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
PRESS RELEASE

published on 10/25/2023 at 13:30, 2 years 10 months ago

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
PRESS RELEASE

published on 10/17/2023 at 14:00, 2 years 10 months ago

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
PRESS RELEASE

published on 09/20/2023 at 13:30, 2 years 11 months ago

Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology

Accesswire

Published on 09/11/2026 at 04:00, 5 hours 58 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 11 hours 33 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 16 hours 12 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 18 hours 38 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 18 hours 58 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 09:20, 38 minutes ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 52 minutes ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 58 minutes ago

Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 58 minutes ago

Picton Property Income Limited - Removal
Published on 09/11/2026 at 09:00, 58 minutes ago

Official List Notice

Les Echos

Published on 09/11/2026 at 07:00, 2 hours 58 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 2 hours 58 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 2 hours 58 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 hours 58 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 14 hours 28 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE